Featured Top Story
The shot, named mFlusiva, is intended for adults age 50 or older.
From
To
Featured Top Story
Moderna's COVID-19 vaccine, Spikevax, had more than $3 billion in sales last year.
The FDA said the new booster option is for adults who can't get one of the updated omicron-targeting Pfizer or Moderna boosters.
Featured Top Story
Officials hope to expand protection against an expected winter surge.
Featured Top Story
U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain.
Featured Top Story
Moderna and Pfizer’s two-shot vaccines both use mRNA technology to help patients fight the coronavirus.
Featured Top Story
About 261 million Americans have received at least one COVID-19 shot, but only 108 million have received a booster.
Featured Top Story
Western states safety review finds Pfizer, Moderna vaccines safe for children as young as six months
The Workgroup provided its confirmation to the Governors of California, Nevada, Oregon, and Washington.
Featured Top Story
A final signoff from the Centers for Disease Control and Prevention is expected this weekend.
Featured Top Story
If all the regulatory steps are cleared, shots should be available next week.